Sandoz has introduced the authorized generic version of Alcon Research Ltd.'s Pataday, an olopatadine hydrochloride ophthalmic solution.
"As a division of Novartis, we are pleased to have the opportunity to further drive access to this critical medicine in the U.S. market,” Sandoz President Peter Goldschmidt said. “By working internally with the Novartis group, Sandoz is able to deliver a wide range of ophthalmic dosage forms that require high technical expertise.”
The olopatadine solution is a mast cell stabilizer that works like an antihistamine. It relieves eye itching caused by allergies by blocking histamine action. The medication is not intended for irritation caused by contact lenses and is for topical use only.
Sandoz is a division of the Novartis Group. It is a leader in generic pharmaceuticals and biosimilars. Its portfolio contains approximately 1,000 items in the major therapeutic areas. Sales in the U.S. were $10.1 million in 2015. Product sales reached more than 500 million patients in 2015.
U.S. sales for Pataday were approximately $293 million between April 2016 and April 2017. Alcon Research Ltd. holds the U.S. registered trademark for Pataday.